The primary objective of this phase 3 trial is to evaluate the efficacy and safety of the addition of the mesenchymal stromal cell (MSC) remestemcel-L plus standard of care compared to placebo plus standard of care in patients with acute respiratory distress syndrome (ARDS) due to SARS-CoV-2.

Primary Outcome Measures :
Number of all-cause mortality [Time Frame: 30 days]
Number of all-cause mortality within 30 days of randomization.

---

"I think the caveat was that our trial has mortality as the primary endpoint."

Read More: https://investorshangout.com/post/newpost/605...z6eJLlPv5I